Cutaneous Malignant Melanoma Incidences Analyzed Worldwide by Skin Type over Advancing Age of Males and Females: Evidence Estrogen and Androgenic Hair are Risk Factors by Godar, Dianne E. et al.
Marquette University
e-Publications@Marquette
Mathematics, Statistics and Computer Science
Faculty Research and Publications
Mathematics, Statistics and Computer Science,
Department of
1-1-2017
Cutaneous Malignant Melanoma Incidences
Analyzed Worldwide by Skin Type over Advancing
Age of Males and Females: Evidence Estrogen and
Androgenic Hair are Risk Factors
Dianne E. Godar
U.S. Food and Drug Administration
Madhan Subramanian
George Washington University
Stephen Merrill
Marquette University, stephen.merrill@marquette.edu
Published version. Journal of Epidemiological Research, Vol. 3, No. 1 (2017): 42-50. DOI. © 2017
Sciedu Press. Used with permission.
http://jer.sciedupress.com Journal of Epidemiological Research 2017, Vol. 3, No. 1
ORIGINAL ARTICLES
Cutaneous malignant melanoma incidences analyzed
worldwide by skin type over advancing age of males
and females: Evidence estrogen and androgenic hair
are risk factors
Dianne E Godar∗1, Madhan Subramanian2, Stephen J Merrill3
1Division of Human Disease Research Worldwide, Body of Knowledge, Inc., USA
2Department of Biomedical Engineering, George Washington University, Washington DC, USA
3Department of Mathematics, Statistics and Computer Science, Marquette University, Milwaukee, USA
Received: August 25, 2016 Accepted: December 7, 2016 Online Published: December 21, 2016
DOI: 10.5430/jer.v3n1p42 URL: http://dx.doi.org/10.5430/jer.v3n1p42
ABSTRACT
We previously analyzed cutaneous malignant melanoma (CMM) incidences worldwide by sex, age, and Fitzpatrick skin type
over time (1955-2007) and found only European-ancestry populations have exponential increasing incidences and about a 2-log
increase in the risk between the youngest age groups (0-14 and 15-29 yr). We proposed the increasing incidence over time may
be from the spread of Human Papilloma Virus (HPV) found in CMM biopsies, and that the 2-log incidence increase between
the youngest age groups might be from developing androgenic hair. The increasing incidence with age may be from white
hairs transmitting UV radiation to follicular melanocytes. Here we analyzed CMM incidences over the advancing age of males
and females of every skin type (I-VI) worldwide. We found only European-ancestry females have a linear increase in their
CMM risk while males of all races have a power function increase in their risk with advancing age. We propose the gradual
loss of HPV-infected androgenic follicles with advancing age of only European-ancestry females during and after menopause
significantly reduces their CMM risk compared to all males who do not have significant estrogen loss and consequent loss of
androgenic hair with advancing age. All other races have females with significantly lower amounts of androgenic body hair so
that its loss with advancing age is not significant. These results combined with those in the literature and our previous findings
showing CMM has been increasing over time, suggests estrogen synergizes HPV infection of androgenic follicular melanocytes
significantly increasing the risk for getting CMM.
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1. INTRODUCTION
Many risk factors have been associated with the initiation
and propagation of cutaneous malignant melanoma (CMM)
including sunlight exposure, DNA damage (both direct and
indirect), ozone depletion, sunburn and sunscreens, photo-
sensitive drugs, cosmetic ingredients, indoor environment,
artificial UV lamps and ionizing radiation, endogenous and
exogenous sex hormones, especially estrogen, pregnancy,
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Disease Research Worldwide, Racine, WI 53403, USA.
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skin type and melanocytic hyperpigmentation, family history
(germline mutations), and DNA polymorphisms. We previ-
ously found the incidence of CMM has been increasing ex-
ponentially exclusively in European-ancestry populations by
analyzing the worldwide temporal (1955-2007) incidences
of males and females in five age groups (0-14, 15-29, 30-49,
50-69, 70-85+) with Fitzpatrick skin types I-VI[1, 2] in 57
countries on six continents using data from the International
Agency for Research on Cancer (IARC).[3] To explain this
temporal exponential increase in CMM, we suggested the ob-
served increasing Human Papilloma Virus (HPV) infection
of nevi and immune-privileged hair follicles[4] along with
decreasing vitamin D3 levels over the past few decades, as
reflected by the inversely related parathyroid hormone,[5] are
responsible.
HPV infection is increasing at an exponential rate in both
Europe[6] and the United States (U.S.)[7] and support for
a role of vitamin D3 came from our analysis of European
CMM incidences which showed a significant increase occurs
with decreasing UVB dose after 1960.[8] HPV is found in
CMM biopsies, nevi,[9] and hair follicles that contain stem
cells.[10] HPV expedients transformation by inactivating p53,
pRB, and vitamin D3 receptor initiated apoptotic pathways
so that the cell survives even with DNA damage.[11–13] The
importance of vitamin D is reflected by the fact that CMM
patients had deficient and insufficient prediagnostic vitamin
D3 levels[14] and survived longer if they got regular sun ex-
posures.[15] Furthermore, outdoor workers have twice the
vitamin D3 levels as indoor workers[16] and they have about
half the risk for getting CMM.[17] And along with provid-
ing another apoptotic pathway for melanoma cells through
the vitamin D3 receptor,[13] vitamin D3 boosts the immune
system by enabling T cells to become activated so they can
kill virally infected and malignant cells.[18] Paradoxically,
in Europe, we found significantly higher CMM incidences
occur with lower UVB doses[8] and besides suggesting lower
levels of vitamin D may be involved, the findings could also
implicate higher levels of UVA exposure in the etiology, as
we and others have previously hypothesized.[19, 20]
Besides the temporal increase in the incidence of CMM, we
also observed a dramatic 2-log increase in the CMM inci-
dence between age groups 0-14 and 15-29.[1] Curiously,
only the European-ancestry Spanish, Italian, and Israeli skin
type III-VI populations had similar CMM profiles as the
European-ancestry skin type I-III populations, while the
non-European skin type III-IV populations like the Chinese,
Japanese, or South Americans (including Koreans and Thai’s,
results not shown) had lower CMM incidences that decreased
or remained stable over time and did not display the dramatic
2-log increase in incidence between the youngest age groups.
We proposed the dramatic increase in the incidence of CMM
between the youngest age groups is from developing andro-
genic body hair because European descendants have the most.
One can obtain some support for this idea by comparing the
distribution of CMM with the distribution of androgenic
body hair over male and female body sites. Males have more
hair that is androgenic on their face, neck, and torso while
females have more hair that is androgenic on their lower
limbs[21] coincident with the body sites CMM is found most
frequently.[22]
Because outdoor workers have a lower CMM incidence than
indoor workers,[17] yet they get three to ten times the annual
UV radiation (UVR; 290 nm - 400 nm) dose that indoor
workers get,[23] we know the cumulative dose of UVR is
not involved in CMM. So why does the incidence of CMM
increase with increasing age if it is not from cumulative UVR
doses? We proposed the increasing CMM incidence with in-
creasing age may be from increasing reactive oxygen species
(ROS) creating white hair that can transmit UVA radiation
(316 nm - 400 nm) along with visible light and possibly some
UVB radiation (290 nm - 315 nm) to follicular melanocytes
and stem cells in the bulge and root areas of the hair folli-
cle.[24] We can obtain some supporting evidence for this idea
from the gray horse model that has protective black skin and
does not get melanoma until its hair turns white.[25]
Here we investigated the role of age and skin type in the
etiology of CMM, in order to address the question raised
by a previous investigation as to why fair-skinned women
have a linear increase in the incidence of CMM with advanc-
ing age while fair-skinned men have a power function.[26]
The investigators proposed a role for estrogen. To help an-
swer this question, we analyzed the CMM incidences over
the advancing age of males and females with Fitzpatrick
skin types I-VI in 57 countries on six continents using data
from IARC.[3] In agreement with previous analysis using
U.S. data for 2005,[26] we also found the incidence of CMM
increases with advancing age as a non-linear, usually power
function increase for all skin type I-III males, while it in-
creases linearly for skin type I-III females. However, our
analysis of the world’s different populations revealed that
not only do fair-skinned people have this phenomena but
that all European-ancestry females have a linear increase
in the incidence of CMM regardless of skin type (I-III or
III-IV) while all males of European or any other–ancestry
have a non-linear, power function increase in the incidence
of CMM with advancing age. Here we propose an answer to
the intriguing question, “Why does CMM increase linearly
over age exclusively in European females regardless of skin
type?”
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2. METHODS
2.1 Analysis of CMM incidence by sex and skin type
over the age of the individual
We analyzed the CMM incidences over the advancing age of
males and females with Fitzpatrick skin types I-III, III-IV, IV-
V, and V-VI[2] around the world using IARC’s age-adjusted,
world population normalized data for the 5-year midpoint
of 2005 (2003-2007).[3] We plotted average ages for the
different age groups, i.e., 0-14 (7 yr), 15-29 (22 yr), 30-49
(40 yr), 50-69 (60 yr) and 70-85+ (80 yr) and aggregated the
regional registries for some countries to estimate national
CMM incidence trends. In order to show that the method
of analysis did not yield misleading results, i.e., using an
average age for each age group range, we also analyzed skin
type I-III New Zealand males and females every 5 years of
age from ages 0-5 to 80-85+ in the year 2005.
To possibly obtain more hints into the etiology of CMM
beyond sex, age, and personal UVR dose, we normalized
the incidence data for all ages 0-85+ of males and females
(averaged) by personal UVR dose and looked at skin types
around the world in the year 2005.
We analyzed 57 countries in total; the data shown here is
for Australia, the U.S. (white, other white, or non-Hispanic
white), Europe (24 countries average shown), China, South
America (6 countries average shown), Spain, Italy, Israel,
New Zealand (Maoris), India, Africa (8 countries average
shown), and the U.S. African-American blacks. The data for
the countries analyzed but not shown here are New Zealand
(non-Maori whites), Canada, Japan, Cuba, Cyprus, Korea,
Kuwait, Malta, Philippines, Portugal, and Thailand.
The specific inclusion criterion was compilation in the last
volume of the CI5 series (volume X). The quality control
involved a detailed assessment of the validity, completeness,
and comparability of the incidence data; these details are pro-
vided online (http://ci5.iarc.fr/CI5I-X/old/vol10/I_08.pdf).
IARC’s CMM data includes all tumor stages, histological
subtypes, thicknesses, and body site locations.
Other details of this analysis, including the skin types and
countries used are given in reference 1.
3. RESULTS
We began by analyzing the CMM incidence of primarily skin
type I-III populations in Australia, U.S., Europe, and Canada,
and curiously found that females display a linear trend over
advancing age, whereas, males have an increasing non-linear
power function over advancing age (see Figure 1).
Figure 1. Age-standardized CMM cases per 100,000 people by age of Australian, U.S., European, and Canadian males and
females with pale skin tone and Fitzpatrick skin type I-III
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In contrast to the skin type I-III populations around the world,
the skin type III-IV populations with yellow skin tone have
lower incidences and only display non-linear power func-
tions over advancing age of both females and males, except
for the Spanish population residing in Spain (see Figure 2).
Figure 2. Age-standardized CMM cases per 100,000 people by age of Chinese, Japanese, Spanish, and South American
(S.A in Figure) males and females with yellow skin tone and Fitzpatrick skin type III-IV
Figure 3. Age-standardized CMM cases per 100,000 people by age of Italian and Israeli males and females with olive skin
tone and Fitzpatrick skin type III-IV; eastern Indian males and females with brown skin tone and Fitzpatrick skin type IV-V;
U.S. African American males and females with brown to black skin tone and Fitzpatrick skin type IV-VI
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The skin type III-IV Europeans with olive skin tone of Ital-
ians and Israelis only had females displaying a linear function
over advancing age (see Figure 3 top panels) similar to skin
type I-III and skin type III-IV Europeans with yellow skin
tone (Spanish females), whereas the males all displayed non-
linear power functions over advancing age. However, the
skin type IV-V populations in India (see Figure 3, bottom left
panel) or the native Polynesian Maori population residing
in New Zealand or the native Polynesian Hawaiian popu-
lation in Hawaii (results not shown) with skin type III-IV
along with the African skin types III-VI (results not shown)
and U.S. African-American black skin tone populations with
skin types IV-VI (see Figure 3 bottom right panel) all have
non-linear power functions for both males and females.
Because the method of analysis involved an average age for
the different age group ranges, the data plots might be deceiv-
ingly linear or another mathematical function. To know how
the incidence of CMM really increases with advancing age
and what mathematical function really applies to European
descendants, we analyzed males and females in New Zealand
every 5 years of age (see Figure 4). The linear increase for
females and power function for males persisted.
Figure 4. Age-standardized CMM cases per 100,000 people
by every five years of age of New Zealand (NZ in Figure)
males and females with pale skin tone and Fitzpatrick skin
type I-III
To obtain more information on the etiology of CMM be-
yond sex, age, and UVB dose, we averaged the CMM inci-
dences of males and females of all ages 0-85+ and normal-
ized by personal, residential UVB dose[8] to compare the
different skin types in countries around the world. Figure
5A shows the European-ancestry populations with skin type
I-III in Australia ([CMM incidence 21.12/100K people/J/m2]
× 10-3) and New Zealand ([33.47/100K people/J/m2] ×
10-3) have about two and three times the CMM incidences,
respectively, as the skin type I-III population in the U.S.
([12.34/100K people/J/m2] × 10-3), Europe ([11.47/100K
people/J/m2] × 10-3), or Canada ([15.51/100K people/J/m2]
× 10-3), which have similar CMM incidences. Figure 5B
shows the Asian populations with skin type III-IV and
yellow skin tone in China ([0.25/100K people/J/m2] ×
10-3), Japan ([0.41/100K people/J/m2] × 10-3), and Korea
([0.58/100K people/J/m2] × 10-3) have much lower CMM
incidences compared with the skin type I-III populations
and have about five to 20 times lower incidences as the
same skin type and yellow skin tone Spanish populations
in South America ([2.60/100K people/J/m2] × 10-3) and
Spain ([4.70/100K people/J/m2] × 10-3). Figure 5C shows
skin type III-IV with olive skin tone Italians ([6.51/100K
people/J/m2]× 10-3) and tan skin tone Polynesian Maori’s in
New Zealand ([5.82/100K people/J/m2] × 10-3) have about
half the CMM incidence as skin type I-III populations in
the U.S., Europe, and Canada, while skin type IV-V east-
ern Indians ([0.20/100K people/J/m2] × 10-3) and skin type
III-VI in Africa ([0.53/100K people/J/m2] × 10-3) or skin
type IV-VI African-American blacks in the U.S. ([0.77/100K
people/J/m2] × 10-3) have very low incidences similar to
the Chinese, Koreans, and Japanese. Note that the African-
American skin types IV-VI in the U.S. have higher CMM
incidences than the lighter skin type IV-V eastern Indians.
4. DISCUSSION
Analysis of the incidence of CMM over advancing age
of males and females around the world reveals that only
European-ancestry females have a linear increase in the in-
cidence with advancing age regardless of Fitzpatrick skin
type (I-III or III-IV): skin type I-III (see Figures 1, 4, 5A);
skin type III-IV (see Figure 2, top left panel, and Figure
5B); skin type IV (see Figure 3, top two panels), skin type
IV-V, and skin type V-VI (see Figure 5C, bottom panels left
to right, respectively). All other females and males have a
non-linear power function increase in the incidence of CMM
with advancing age (see Figure 2 top two panels and bottom
right panel, Figure 3 bottom two panels). Because a past
investigation only used U.S. data, this linear increase in the
incidence of CMM over advancing age was thought to be
true for only skin type I-III females.[26] As a result of our
worldwide findings showing similar linear increases over age
for Fitzpatrick skin type III-IV, we must now address the
question, “Why does CMM increase linearly over advancing
age exclusively in European-ancestry females regardless of
skin type?” We propose the significant gradual lose of bodily
androgenic hair during and after menopause in aging Euro-
pean females (p < .001)[27] reduces the risk for getting CMM
relative to all males who do not undergo menopause and do
not lose as much bodily androgenic hair as they age, and
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other females with lower amounts of androgenic hair lose
less hair with age.
Figure 5. Incidence of CMM per 100,000 people
normalized by personal UVB dose (J/m2)*10-3 for A)
Fitzpatrick skin type I-III pale skin tone European-ancestry
populations, B) Fitzpatrick skin type III-IV with yellow skin
tone populations, and C) Fitzpatrick skin type III-IV with
olive skin tone Italian and Maori populations, Fitzpatrick
skin type IV-V with brown skin tone eastern Indian
population, Fitzpatrick skin type III-VI olive, brown, and
black skin tone African populations, and Fitzpatrick skin
type with brown to black skin tone U.S. African American
populations
We can find more evidence that bodily androgenic hair is a
major risk factor for getting CMM when we compare the inci-
dences around the world by skin type. We expect darker skin
types to be more protective than lighter skin types against
UVR-induced damage, so that the order of increase in the
incidence of CMM should be by decreasing skin type VI to I.
Surprisingly, when we compare the different skin types, we
sometimes observe the opposite increase in CMM incidence.
For example, skin type IV-VI African-Americans in the U.S.
who get lower UVB doses (∼9,500-15,000 J/m2/yr.) than
lighter skin type IV-V in India (∼14,000-20,000 J/m2/yr.)
have about three times the incidence of CMM (compare bot-
tom panels in Figure 3 and Figure 5C). Further evidence is
obtained from the Northern European skin type I-III pop-
ulations who, along with the Mediterranean populations,
evidently have the most androgenic hair of any population
anywhere in the world and also have the highest incidence of
CMM in Europe.[8] Paradoxically, they receive some of the
lowest annual UVB doses in the world[23] other than Switzer-
land, Norway, Iceland, and Sweden. When we compare the
skin type III-IV populations, we see a very curious phenom-
ena that adds even more evidence that bodily androgenic
hair is probably a major risk factor for getting CMM. The
Chinese and Japanese populations (see Figure 2 top panels;
including the Koreans and Thai, results not shown) have al-
most ten times lower CMM incidences as the Spanish and
South American males and females (see Figure 2 bottom
panels); the Chinese have some of the lowest percentages of
androgenic body hair with about half the amount that whites
have[28] and the Japanese have about half the amount that
the Germans have[29] who are similar to the Swedes[30] and
the European-ancestry populations in North America.[31] For
skin type III-IV with olive skin tone, the Italian and Israeli
Mediterranean populations (see Figure 3 top panels) with the
most androgenic body hair, shows a disproportionate CMM
incidence for this skin type compared with the lighter yellow
skin tone Spanish and South American skin type III-IV. This
may be because they have similar (about 20 to 40 for Italians)
or much higher incidences (about 40 to 80 for Israelis) of
CMM, which also goes against the belief that skin pigment
is protective for CMM, while it adds further support for the
belief that the amount of bodily androgenic hair increases
the CMM risk. This suggests skin pigment is only somewhat
protective against CMM as it also impedes penetration of
UVR to the follicular melanocytes.
To obtain more information about the etiology of CMM
beyond sex, age, and personal UVR dose, we normalized
the average male and female incidence data for all ages
(0-85+ yr.) by personal UVB dose which was shown not
to correlate with the incidence of CMM in the U.S.[32] We
observe that the skin type I-III European-ancestry popula-
tions in Australia and New Zealand have two to three times
higher CMM incidences, respectively, than the skin type I-
III populations in the U.S., Europe or Canada, which have
similar incidences (see Figure 5A). Because UVB is not a
factor in this analysis and bodily androgenic hair of Euro-
pean descendants around the world is similar, these differ-
ences align with the observed melanocortin-1-receptor gene
variants associated with CDKN2A mutation carriers found
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in Australia (and possibly more in New Zealand) that are
almost twice as many as those found in Europe.[33] Aus-
tralia and New Zealand have Europeans who primarily em-
igrated from England, especially Wales, and Ireland with
populations having the highest percentages of red-haired
people in the world. More evidence supporting the notion
that red hair is important is seen in Figure 5B, where the
Chinese, Japanese, and Koreans (along with the Thai, re-
sults not shown) having black hair and low percentage of
androgenic body hair and they also have the lowest CMM
incidences of all the world’s populations with skin type III-
IV. The European Spanish population has almost 10 times
the incidence that the Asians have and they have consider-
ably more androgenic body hair and some red-haired people
with melanocortin-1-receptor variants,[34] whereas the Span-
ish population in South America that bred with the natives
have only about five times the CMM incidence and also have
lower percentages of bodily androgenic hair. Figure 5C of-
fers more evidence for red hair and melanocortin-1-receptor
variants, as the skin type III-IV Italians have more red-haired
people and melanocortin-1-receptor variants (and the most
androgenic body hair) than the Asian-Indians or Africans
(and presumably also the African Americans in the U.S.)
who have almost no red hair melanocortin-1-receptor vari-
ants (and much lower percentages of androgenic hair) while
Britain and Ireland have the most melanocortin-1-receptor
variants.[35] The one exception that stands out are the skin
type III-IV Polynesian Maori’s residing in New Zealand who
have a CMM incidence almost as high as the Italians and
they also have red haired people.[36] The synthesis of red
hair’s pheomelanin produces ROS that are not absorbed by
that protein as they are by black hair’s eumelanin, so that
protection against oxidative damage especially to the DNA
bases cannot occur.[37] In addition, the aging process pro-
duces increasing amounts of ROS primarily due to increasing
mitochondrial dysfunction.[38]
Apparently the trifecta for getting melanoma involves es-
trogen and its receptors, HPV, and ROS. Estrogen plays a
significant role in the maintenance and development of the
hair follicle,[39] an immune privileged site for HPV to hide.[4]
Evidence that estrogen synergizes with HPV is provided by
cervical cancer,[40] showing that estrogen is responsible for
the onset, persistence, and malignant transformation of cer-
vical cells.[41] The mechanism involves estrogen stimulating
oncogene expression of HPV E6 and E7 proteins and promot-
ing viral proliferation.[42] ROS synergizes with estrogen to
cause cancer,[43] it activates HPV,[44] and HPV’s E6 protein
can in turn cause production of ROS and DNA damage.[45]
The estrogen receptor alpha also plays an important role
in this transformation process[40, 46] and low levels of vita-
min D3 help promote cervical cancer.[47] This perfect storm
for initiating and promoting cervical cancer probably also
applies to other HPV-related cancers like CMM. CMM is
also influenced by estrogen and its receptors,[49] over half
the biopsies contain HPV,[49] and both dark (pheomelanin
synthesis) and light (UVA exposures) ROS production play
significant roles in the initiation of melanoma.[50]
5. CONCLUSIONS
Diseases that involve several causative or potentially
causative agents can result in confusing and contradictory
studies. Here, we attempt to put together a coherent picture
of factors leading to the initiation of CMM that is consistent
with the extensive epidemiological information throughout
the world. The interaction of melanocytic stem cells, estro-
gen, HPV, vitamin D3, UV exposure, and age, results in the
story of the incidence rates of CMM across the world.
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